Scarica l'app Stockscreener
0.834
4.25%
0.034
Precedente Chiudi:
$0.80
Aprire:
$0.8
Volume 24 ore:
1.13M
Relative Volume:
0.86
Capitalizzazione di mercato:
$99.54M
Reddito:
-
Utile/perdita netta:
$-25.91M
Rapporto P/E:
-3.3135
EPS:
-0.2517
Flusso di cassa netto:
$-22.73M
1 W Prestazione:
+3.93%
1M Prestazione:
-8.17%
6M Prestazione:
-21.32%
1 anno Prestazione:
-11.30%
Intervallo 1D:
$0.7832
$0.846
Intervallo di 1 settimana:
$0.7601
$0.846
Portata 52W:
$0.7301
$1.51
Oncolytics Biotech Inc Stock (ONCY) Company Profile
Nome
Oncolytics Biotech Inc
Settore
Industria
Telefono
(403) 670-7377
Indirizzo
SUITE 325, 4350 EXECUTIVE DRIVE, SAN DIEGO, AB
Compare ONCY vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ONCY
Oncolytics Biotech Inc
|
0.834 | 98.31M | 0 | -25.91M | -22.73M | -0.2517 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-13 | Iniziato | Lake Street | Buy |
| 2022-10-06 | Iniziato | Maxim Group | Buy |
| 2021-02-17 | Iniziato | H.C. Wainwright | Buy |
Oncolytics Biotech Inc Borsa (ONCY) Ultime notizie
ONCY Stock Heads For Sixth Straight Session Of Gains – Lead Therapy Shines in Early Combination Treatment Study - Stocktwits
Oncolytics Biotech (NASDAQ:ONCY) Announces Quarterly Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat
ONCY: Net loss increased to $9.4M in Q2 2026, with cash needs exceeding current resources - TradingView
IMDX Stock Price and Chart — NASDAQ:IMDX - TradingView
Oncolytics Biotech Inc (ONCY) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Oncolytics Biotech (ONCY) Expected to Post Quarterly Earnings on Friday - MarketBeat
Why Overall Survival May Be Becoming Oncology’s Most Important Metric (NASDAQ: ONCY) - Barchart.com
Oncolytics Biotech | 10-Q: Q1 2026 Earnings Report - Moomoo
ONCY News | ONCOLYTICS BIOTECH INC (NASDAQ:ONCY) - ChartMill
Oncolytics Biotech Inc (ONCY) Valuation: PE, PB & Fair Value Analysis - tradingkey.com
ONCY Q2'26 Earnings: EPS estimate is (0.05) USD - TradingView
Oncolytics Biotech Inc (ONCY) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Weekly Recap: Pelareorep FDA Fast Track and Nasdaq sub-$1 notice - TradingView
Oncolytics Biotech Inc (ONCY) Balance Sheet - TradingKey
Oncolytics Biotech Inc (ONCY) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Oncolytics Biotech Inc (ONCY) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Oncolytics Biotech Inc (ONCY) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ONCY|Oncolytics Biotech Inc|Price:0.810|Chg%:-0.002 - TradingKey
ONCY|Oncolytics Biotech Inc|Price:0.812|Chg%:-0.036 - TradingKey
ONCY|Oncolytics Biotech Inc|Price:0.784|Chg%:-0.016 - TradingKey
Oncolytics Biotech Inc. (ONCY) Files 8-K Notice of Nasdaq Delisting or Listing Rule Deficiency – July 2026 - Minichart
Oncolytics Biotech Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
ONCY Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Oncolytics (ONCY) Receives FDA Fast Track Designation for Pelare - GuruFocus
Oncolytics Biotech Inc - Baystreet.ca
Stocks in play: Oncolytics Biotech Inc - Barchart.com
Viral Immunotherapy Gets FDA Fast Track for Anal Cancer Patients Without Options - Tech Times
Oncolytics wins US FDA Fast Track for pelareorep in anal cancer - AllSci
FDA grants fast track status to Oncolytics’ anal cancer therapy By Investing.com - Investing.com South Africa
Oncolytics Biotech Gets US FDA Fast Track Designation for Pelareorep Combination in Anal Cancer Treatment - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
Oncolytics receives FDA Fast Track for pelareorep plus checkpoint inhibitor in second-line+ anal cancer - TradingView
FDA grants fast track status to Oncolytics’ anal cancer therapy - Investing.com
Investigational anal cancer therapy posts 30% response rate - Stock Titan
Daily Brief Health Care: First Wave BioPharma , NeuroSpectrum Insights, Mesoblast Ltd, Know Labs , Zoetis Inc, CTT Pharmaceutical Holdings, Oncolytics Biotech, ATAI Life Sciences NV and more - Smartkarma
ONCY: Seeking Registration Pathway for Part B of REO 033 Trial - Smartkarma
MSN Money - MSN
Oncolytics Biotech (ONCY) Edges Lower Amid Light Trading – Key Levels in FocusSign of Weakness - dars.gov.et
Oncolytics Biotech Shares Rise on FDA Meeting Plan, Trial Progress in Colorectal Cancer - Moomoo
H.C. Wainwright reiterates Oncolytics Biotech stock rating on trial progress - Investing.com UK
H.C. Wainwright reiterates Oncolytics Biotech stock rating on trial progress By Investing.com - Investing.com South Africa
Oncolytics advances colorectal cancer trial, plans FDA meeting - Investing.com UK
Oncolytics Biotech shares climb ahead of planned FDA meeting on REO 033 trial (ONCY) - MSN
Oncolytics advances colorectal cancer trial, plans FDA meeting By Investing.com - Investing.com South Africa
Oncolytics Biotech Shares Climb Ahead of Planned FDA Meeting on REO 033 Trial (ONCY) - Yahoo Finance
Oncolytics (ONCY) Updates on REO 033 Clinical Study Progress - GuruFocus
Oncolytics Biotech stock jumps on FDA meeting plans for trial By Investing.com - Investing.com Canada
Oncolytics Biotech stock jumps on FDA meeting plans for trial - Investing.com
Oncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial - The Manila Times
Oncolytics Biotech Announces Rapid REO 033 Site Activation and FDA Meeting on Registrational Pathway for Pelareorep in Metastatic Colorectal Cancer - Quiver Quantitative
Oncolytics Biotech Inc Azioni (ONCY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):